A. Monforte

发表

Female gender is associated with long COVID syndrome: a prospective cohort study

F. Bai, D. Tomasoni, Camilla Falcinella, 2021, Clinical Microbiology and Infection.

The Development of Artificial Neural Networks to Predict Virological response to Combination HIV Therapy

Brendan Larder, Lidia Ruiz, Andrew Revell, 2007, Antiviral therapy.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

Jonathan AC Sterne, Peter Reiss, Caroline A Sabin, 2002, The Lancet.

Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients.

A. Phillips, J. Lundgren, A. Monforte, 1997, Scandinavian journal of infectious diseases.

Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome

V. Vullo, A. Antinori, C. Mussini, 2011, Antiviral therapy.

Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.

F. Baldanti, F. Ceccherini‐Silberstein, R. Maserati, 2010, The new microbiologica.

IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents

Mardge H. Cohen, J. Nachega, J. Montaner, 2015, Journal of the International Association of Providers of AIDS Care.

Medical and Societal Consequences of Late Presentation

A. Mocroft, A. Monforte, S. Moreno, 2010, Antiviral therapy.

Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing

C. Sabin, A. Monforte, E. Girardi, 2007, Journal of acquired immune deficiency syndromes.

Abacavir use and risk of recurrent myocardial infarction: the D: A: D study

A. Mocroft, O. Kirk, R. Weber, 2018 .

Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

O. Kirk, R. Weber, C. Sabin, 2013, AIDS.

Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study

A. Mocroft, C. Sabin, A. Phillips, 2016, Antiviral therapy.

Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections.

M. Moroni, G. Ippolito, E. Nicastri, 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS

M. Moroni, S. Antinori, A. Monforte, 1997, AIDS.

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

C. Sabin, P. Reiss, J. Lundgren, 2010, AIDS.

Triglycerides / HDL Ratio And Its Impact On Risk Of Diabetes Mellitus Development During 1 Antiretroviral Therapy 2 Short running title : Triglycerides / HDL Ratio and Diabetes ' risk 3

A. Antinori, P. Lorenzini, A. Monforte, 2017 .

Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients

A. Lazzarin, P. Cinque, A. Monforte, 1996, AIDS.

Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?

A. Monforte, P. Cicconi, M. Lichtner, 2007, AIDS.

T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis

F. Bai, E. Suardi, G. Marchetti, 2012, PloS one.

Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression

F. Ceccherini‐Silberstein, A. De Luca, A. Monforte, 2016, Medicine.

Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients

O. Kirk, C. Sabin, P. Reiss, 2005, Antiviral therapy.

Prevalence of Hypovitaminosis D and Factors Associated With Vitamin D Deficiency and Morbidity Among HIV-Infected Patients Enrolled in a Large Italian Cohort

V. Vullo, A. Antinori, V. Tozzi, 2011, Journal of acquired immune deficiency syndromes.

Deteriorating renal function and clinical outcomes in HIV-positive persons

A. Mocroft, O. Kirk, J. Gatell, 2014, AIDS.

Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting.

A. Mocroft, M. Johnson, J. Lundgren, 2020, Journal of acquired immune deficiency syndromes.

Cessation of cigarette smoking and the impact on cancer incidence in HIV-positive persons : The D : A : D Study

A. Mocroft, R. Weber, C. Sabin, 2018 .

Cutaneous B-cells non-Hodgkin's lymphoma in a HIV-infected female

A. Monforte, T. Bini, A. Cappelletti, 2005, Scandinavian journal of infectious diseases.

Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems

F. Chiodo, A. Monforte, C. Perno, 2004, Antiviral therapy.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

A. Mocroft, O. Kirk, P. Reiss, 2016, The lancet. HIV.

Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe.

A. Mocroft, F. Antunes, V. Soriano, 2010, The Journal of antimicrobial chemotherapy.

Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression

Ross J. Harris, J. Sterne, A. Mocroft, 2009, Journal of acquired immune deficiency syndromes.

Reply to Brumme and Harrigan

F. Ceccherini‐Silberstein, A. Monforte, C. Perno, 2005 .

Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study.

S. Lazzaroni, E. Buscarini, P. Lampertico, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients.

A. Antinori, P. Cinque, V. Tozzi, 2006, AIDS research and human retroviruses.

Patients presenting with AIDS in the HAART era: a collaborative cohort analysis

C. Sabin, J. Miro, M. Johnson, 2008, AIDS.

Major depression‐related immunological changes and combination antiretroviral therapy in HIV‐seropositive patients

A. Monforte, A. Alciati, F. Brambilla, 2007, Human psychopharmacology.

A. Antinori, A. Monforte, M. Trotta, 2002, Journal of acquired immune deficiency syndromes.

The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study.

O. Kirk, C. Sabin, A. Phillips, 2011, The Journal of infectious diseases.

Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy

C. Tincati, G. Marchetti, A. Monforte, 2008, AIDS.

Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system

A. Lazzarin, P. Cinque, A. Monforte, 1993, The Lancet.

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

J. Sterne, F. Lampe, T. Sterling, 2017, The lancet. HIV.

What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres

A. Giacomelli, S. Antinori, F. Bai, 2022, Antimicrobial resistance and infection control.

Body Habitus Changes and Metabolic Alterations in Protease Inhibitor‐Naive HIV‐1‐Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors

M. Moroni, E. Gianelli, A. Monforte, 2002, Journal of acquired immune deficiency syndromes.

Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect

Andrea Cona, Ottavia Viganò, G. Marchetti, 2020, Journal of chemotherapy.

Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals.

V. Vullo, A. Antinori, V. Tozzi, 2008, AIDS patient care and STDs.

Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.

P. Narciso, A. Antinori, A. De Luca, 2003, AIDS.

Microbial Translocation and dysbyosis : extensive immune phenotyping during 1 year of successful combination Antiretroviral Therapy ( cART )

A. Monforte, 2017 .

A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia

A. Zangrillo, A. Monforte, G. Landoni, 2022, Infectious Diseases and Therapy.

Identification of HIV-1-specific regulatory T-cells using HLA class II tetramers

M. Altfeld, M. Addo, A. Antinori, 2012, AIDS.

Evaluation of virological response to antiretroviral therapy in patients carrying HIV-1 non-B subtypes according to baseline mutational patterns

A. Monforte, C. Balotta, 2013 .

High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects

A. Antinori, A. Cingolani, A. Monforte, 2016, Medicine.

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients

F. Bai, C. Tincati, G. Marchetti, 2012, PloS one.

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era

A. Antinori, A. Cingolani, G. Marchetti, 2021 .

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future

M. Sandhu, O. Kirk, M. Rosińska, 2016 .

Salivary stone lithotripsy in the HIV patient.

M. Moroni, A. Monforte, P. Capaccio, 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

Relative Prognostic Value of Self-Reported Adherence and Plasma Nnrti/Pi Concentrations to Predict Virological Rebound in Patients Initially Responding to Haart

D. Nauwelaers, P. Narciso, A. Antinori, 2004, Antiviral therapy.

Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.

Ross J. Harris, J. Sterne, A. Mocroft, 2008, Antiviral therapy.

Risk of Myocardial Infaction with Exposure to Specific ARV from the PI, NNRTI, And NRTI Drug Classes: The D:A:D Study

R. Weber, C. Sabin, P. Reiss, 2009 .

Lipid profiles in HIV-1-infected individuals receiving combination antiretroviral therapy: are different protease inhibitors or non-nucleoside reverse transcriptase inhibitors associated with different lipid profiles?

O. Kirk, C. Sabin, P. Reiss, 2004 .

Class of antiretroviral drugs and the risk of myocardial infarction.

O. Kirk, R. Weber, C. Sabin, 2007, The New England journal of medicine.

CD8+ hyperactivation and senescence correlate with early carotid intima-media thickness in HIV+ patients with no cardiovascular disease.

F. Bai, C. Tincati, G. Marchetti, 2009, Journal of acquired immune deficiency syndromes.

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.

V. Calvez, F. Ceccherini‐Silberstein, C. Katlama, 2010, The Journal of antimicrobial chemotherapy.

Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for european patients with acquired immunodeficiency syndrome

B. Clotet, C. Katlama, J. Gatell, 1995 .

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

J. Sterne, O. Kirk, C. Tural, 2015, Journal of acquired immune deficiency syndromes.

Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study

R. Weber, C. Sabin, P. Reiss, 2008 .

Changes in lymphocyte subsets in depressed HIV-infected patients without antiretroviral therapy.

A. Monforte, A. Alciati, C. Mellado, 2001, Psychosomatics.

The Need for Data on Women Living with HIV in Europe

M. Johnson, A. Monforte, C. Miralles, 2013, Antiviral therapy.

Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected Patients with High and Low CD4+ T-Cell Counts

A. Mocroft, R. Weber, J. Gatell, 2007, Antiviral therapy.

Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment

C. Tincati, G. Marchetti, A. Monforte, 2014, PloS one.

Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals: The D:A:D Study

O. Kirk, C. Sabin, A. Phillips, 2013, Journal of acquired immune deficiency syndromes.

Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US

J. Sterne, M. Bickel, T. Sterling, 2015, Antiviral therapy.

Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study

O. Kirk, R. Weber, C. Sabin, 2003, AIDS.

Predictive factors of hyperhomocysteinemia in HIV-positive patients.

A. Monforte, P. Cicconi, T. Bini, 2007, Journal of acquired immune deficiency syndromes.

Lipid profiles on therapy with PI: The D:A:D (Data collection on adverse events of anti-HIV drugs) study

O. Kirk, R. Weber, C. Sabin, 2002 .

Distinguishable Lipid Profiles between PI and NNRTI Therapy may carry different risk of cariovascular disease (CVD)

O. Kirk, R. Weber, C. Sabin, 2002 .

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

O. Kirk, R. Weber, C. Sabin, 2010, The Journal of infectious diseases.

Sexual behaviour of heterosexual individuals with HIV infection naive for antiretroviral therapy in Italy

M. Moroni, G. Ippolito, D. Serraino, 2001, Sexually transmitted infections.

Sexual behaviour of women living with HIV/AIDS naïve for antiretroviral therapy: The ICONA-BEHEPI Study

G. Ippolito, V. Vullo, D. Serraino, 2000, AIDS care.

Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.

M. Moroni, E. Gianelli, A. Monforte, 2002 .

Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens.

A. Monforte, A. Riva, M. Galli, 2001, Journal of acquired immune deficiency syndromes.

Exposure to Haart is associated with and increased risk of myocardial infarction: the D:A:D study

O. Kirk, R. Weber, C. Sabin, 2003 .

Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)

O. Kirk, R. Weber, C. Sabin, 2009, Circulation.

Predictors of low ovarian reserve in cART-treated women living with HIV

M. Augello, M. Allegrini, C. Tincati, 2021, Medicine.

Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy

E. Seminari, A. Lazzarin, A. Antinori, 2010, Antiviral therapy.

HIV-induced immunodeficiency and Risk of Fatal AIDS-defining and non-AIDS-defining Malignancies: Results from the D:A:D Study

R. Weber, C. Sabin, A. Phillips, 2007 .

Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid.

F. Baldanti, A. Lazzarin, M. Furione, 1995, The Journal of infectious diseases.

Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries

J. Sterne, A. Mocroft, M. Egger, 2015 .

Viral Interference Between Hepatitis B, C, and D Viruses in Dual and Triple Infections in HIV-Positive Patients

M. Capobianchi, A. Monforte, P. Cicconi, 2009, Journal of acquired immune deficiency syndromes.

Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role?

C. Tincati, G. Marchetti, A. Monforte, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Response to Haart and Gb Virus Type C Coinfection in a Cohort of Antiretroviral-Naive HIV-Infected Individuals

G. Ippolito, M. Capobianchi, A. Monforte, 2005, Antiviral Therapy.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Ross J. Harris, J. Sterne, A. Mocroft, 2008, The Lancet.

NON-A,NON-B HEPATITIS IN MILAN

M. Moroni, A. Monforte, F. Caredda, 1981, The Lancet.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Ross J. Harris, J. Sterne, A. Mocroft, 2008, The Lancet.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Stephen R Cole, Jonathan A C Sterne, Ross Harris, 2009, The Lancet.

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Anne M Johnson, Hansjakob Furrer, Peter Reiss, 2013, PLoS medicine.

Effect of Hepatitis C Treatment on Cd4+ T-C El L Counts And The Risk Of Death In HIV–HCV-Coinfected Patients: The Cohere Collaboration

B. Ledergerber, F. Dabis, A. Monforte, 2012, Antiviral therapy.

Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.

A. Monforte, T. Bini, M. Bongiovanni, 2003, Dermatology online journal.

Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies

Ross J. Harris, J. Sterne, A. Mocroft, 2008, Antiviral Therapy.

Renal microsporidiosis due to Encephalitozoon cuniculi in an HIV/AIDS patient with persistent fever and kidney injury.

F. Bai, M. Augello, G. Marchetti, 2021, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid.

A. Lazzarin, P. Cinque, A. Monforte, 1992, The Journal of infectious diseases.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

O. Kirk, R. Weber, C. Sabin, 2014, The Lancet.

Potential predictive factors of osteoporosis in HIV-positive subjects.

F. Sardanelli, G. Cornalba, A. Monforte, 2006, Bone.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

PERSISTENCE OF CIRCULATING HBsAg/IgM COMPLEXES IN ACUTE VIRAL HEPATITIS, TYPE B: AN EARLY MARKER OF CHRONIC EVOLUTION

A. Monforte, R. Franchis, M. Vecchi, 1982, The Lancet.

The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?

R. Bruno, A. Monforte, T. Ferraro, 2004, Antiviral therapy.

Self‐Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection

A. Wu, M. Moroni, P. Narciso, 2001, Journal of acquired immune deficiency syndromes.

Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study

O. Kirk, R. Weber, C. Sabin, 2010, AIDS.

Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis

B. Ledergerber, J. Lundgren, F. Dabis, 2005, Antiviral Therapy.

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients

M. Moroni, G. Filice, P. Narciso, 2000, AIDS.

O. Kirk, R. Weber, C. Sabin, 2006, Archives of internal medicine.

Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

A. Mocroft, O. Kirk, V. Soriano, 2013, Journal of hepatology.

Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy

A. Wu, A. Antinori, A. Monforte, 2002, Journal of acquired immune deficiency syndromes.

Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients

Nina Friis-Møller, Peter Reiss, Rainer Weber, 2008, Diabetes Care.

Decreased Mitochondrial Dna Content in Subcutaneous Fat from HIV-Infected Women Taking Antiretroviral Therapy as Measured at Delivery

C. Giovane, E. Ferrazzi, C. Mussini, 2011, Antiviral therapy.

Therapeutic Monitoring and Variability of Atazanavir in HIV-Infected Patients, With and Without HCV Coinfection, Receiving Boosted or Unboosted Regimens

C. Tinelli, R. Maserati, A. Monforte, 2011, Therapeutic drug monitoring.

The challenge of IL-2 immunotherapy in HIV disease: "no through road" or turning point?

C. Tincati, G. Marchetti, A. Monforte, 2008, Current HIV research.

Italian multicentre study of didanosine compassionate use in advanced HIV infection

M. Moroni, A. Lazzarin, A. Monforte, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.

J. Sterne, M. Egger, R. Hogg, 2006, The Journal of infectious diseases.

Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe

A. Mocroft, O. Kirk, J. Gatell, 2006, Journal of acquired immune deficiency syndromes.

Role of HLA Class I ( HLA-A , B ) and HLA Class II ( HLA-DRB , DQB ) in HIV-1 Patients With and Without Pulmonary Tuberculosis

F. Bai, C. Tincati, G. Marchetti, 2009 .

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART

M. Clerici, M. Magnani, G. Marchetti, 2006, AIDS.

Evolution of HVR-1 Quasispecies after 1-Year Treatment in HIV/HCV-Coinfected Patients According to the Pattern of Response to Highly Active Antiretroviral Therapy

G. Ippolito, M. Capobianchi, A. Monforte, 2006, Antiviral therapy.

681 Solmone

G. Ippolito, M. Capobianchi, A. Monforte, 2006 .

Exposure to antiretroviral therapy and the risk of liver-related death: Is there an association? Results from the D :A :D study group

R. Weber, C. Sabin, P. Reiss, 2006 .

Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure

F. Ceccherini‐Silberstein, F. Gago, A. Antinori, 2004, AIDS.

Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction.

A. Lazzarin, C. Bréchot, A. Monforte, 1992, The Journal of infectious diseases.

Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances: Results from a randomized controlled trial.

F. Bai, A. Monforte, F. Castelli, 2019, AIDS.

Durability of Lopinavir/Ritonavir Monotherapy in Individuals with Viral Load ≦50 Copies/Ml in an Observational Setting

A. Lazzarin, A. Antinori, M. Andreoni, 2014, Antiviral therapy.

What Do We Know about Antiretroviral Treatment of HIV in Women?

A. Monforte, Jane Anderson, Antonella d'Arminio Monforte, 2013, Antiviral therapy.

Mother-to-Child Transmission of Hepatitis C Virus Detected by Nested Polymerase Chain Reaction

A. Lazzarin, C. Bréchot, A. Monforte, 1992 .

High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations

F. Ceccherini‐Silberstein, F. Gago, A. Antinori, 2005, Journal of Virology.

Predictors of severe hyperbiliruniaemia in HIV-infected patients treated with atazanavir (ATV)

A. Monforte, P. Cicconi, A. Barassi, 2008 .

Delayed Presentation and Late Testing for HIV: Demographic and Behavioral Risk Factors in a Multicenter Study in Italy

G. Ippolito, D. Serraino, P. Pezzotti, 2004, Journal of acquired immune deficiency syndromes.

Outcome of a Second‐Line Protease Inhibitor‐Containing Regimen in Patients Failing or Intolerant of a First Highly Active Antiretroviral Therapy

A. Monforte, B. Castelnuovo, F. Adorni, 2000, Journal of acquired immune deficiency syndromes.

Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors

Valentina Svicher, Francesca Ceccherini-Silberstein, F. Ceccherini‐Silberstein, 2005, Antimicrobial Agents and Chemotherapy.

Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy

C. Mussini, A. Monforte, F. Mazzotta, 2008, AIDS.

High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma

A. Monforte, F. Mainini, A. Gori, 1996, AIDS.

Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study.

H. Schuitemaker, C. Sabin, R. Geskus, 2014, The lancet. HIV.

Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study

F. Ceccherini‐Silberstein, A. Antinori, A. De Luca, 2014, BMC Infectious Diseases.

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19

F. Bai, G. Marchetti, A. Monforte, 2023, Clinical Microbiology and Infection.

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection

A. Mocroft, O. Kirk, A. Phillips, 1999, The Lancet.

JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy

P. Ascierto, A. Mortara, A. Vannucchi, 2021, Journal of clinical medicine.

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy

Alessandro Cozzi-Lepri, M. Moroni, F. Chiodo, 2004, AIDS.

Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients

F. Bai, C. Tincati, G. Marchetti, 2017, AIDS.

EPIDEMIOLOGY OF NON-A, NON-B HEPATITIS

M. Moroni, A. Monforte, F. Caredda, 1979, The Lancet.

Resilience, Psychological Well-Being and Daily Functioning Following Hospitalization for Respiratory Distress Due to SARS-CoV-2 Infection

A. Priori, G. Pravettoni, K. Mazzocco, 2021, Healthcare.

T-Cell Phenotype and Function following a First cART Regimen Containing Either a Protease Inhibitor or a Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Late Presenters: Results from a Retrospective, ex vivo Study

C. Tincati, G. Marchetti, A. Monforte, 2015, Antiviral therapy.

Successful Direct-Acting Antiviral Therapy (DAA) in HIV/HCV Co-Infected Patients Fails to Restore Circulating Mucosal-Associated Invariant T Cells (MAITs)

P. Klenerman, G. Marchetti, A. Monforte, 2019 .

Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males

G. Parati, P. Soler-Palacín, M. Girardis, 2021, EBioMedicine.

OP-JANM180350 1..11

F. Ceccherini‐Silberstein, M. Capobianchi, A. Antinori, 2018 .

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements

Ross J. Harris, J. Sterne, A. Mocroft, 2009, AIDS.

Serum alpha-fetoprotein levels predict early virologic response in HIV-positive subjects treated for chronic hepatitis C.

C. Tincati, G. Marchetti, A. Monforte, 2008, Journal of acquired immune deficiency syndromes.

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

O. Kirk, R. Weber, C. Sabin, 2008, AIDS.

Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice: Results From the Italian Cohort of Antiretroviral-Naive Patients

M. Moroni, A. De Luca, C. Mussini, 2005, Journal of acquired immune deficiency syndromes.

Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions: The Istituto Superiore di Sanità-Pulsed Antiretroviral Therapy (ISS-PART) Study

A. Monforte, L. Palmisano, F. Castelli, 2007, Journal of acquired immune deficiency syndromes.

The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.

Giulia Marchetti, C. Tincati, G. Marchetti, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Absence of CD 4 + T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy : Clinical Risk , Immunological Gaps , and Therapeutic Options

C. Tincati, G. Marchetti, A. Monforte, 2009 .

Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons.

A. Wu, A. Antinori, A. Monforte, 2004, Psychosomatics.

Relationship Between HAART Adherence and Adipose Tissue Alterations

A. Wu, A. Antinori, A. Monforte, 2002, Journal of acquired immune deficiency syndromes.

Patient-reported and physician-estimated adherence to HAART

Albert W. Wu, Rita Murri, A. Wu, 2004, Journal of General Internal Medicine.

Correlates and Predictors of Adherence to Highly Active Antiretroviral Therapy: Overview of Published Literature

A. Wu, P. Narciso, A. Antinori, 2002, Journal of acquired immune deficiency syndromes.

The HIV continuum of care in European Union countries in 2013: data and challenges

Delpech, C. Sabin, P. Reiss, 2017 .

Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment

E. Nicastri, A. Antinori, G. Marchetti, 2013, AIDS.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

A. Mocroft, O. Kirk, B. Clotet, 2008, AIDS.

Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study.

A. Monforte, A. di Biagio, T. Bini, 2005, AIDS.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

A. Monforte, P. Cicconi, A. di Biagio, 2005, International journal of antimicrobial agents.

Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy.

C. Tincati, G. Marchetti, A. Monforte, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mycobacterium avium Subspecies paratuberculosis Bacteremia in Type 1 Diabetes Mellitus : An Infectious Trigger ?

A. Monforte, L. Ferraris, A. Gori, 2022 .

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

G. Ippolito, M. Capobianchi, A. De Luca, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era

A. Antinori, A. Cingolani, G. Marchetti, 2021, AIDS (London, England).

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

W. Rodriguez-Cintron, J. Vincent, P. Koul, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected patients with High and Low CD4+ T-cell Counts

A. Mocroft, R. Weber, A. Phillips, 2006, Antiviral Therapy.

A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients

M. Moroni, A. Lazzarin, P. Cinque, 1996, Journal of Neurology.

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study

A. Mocroft, R. Weber, C. Sabin, 2017, PLoS medicine.

CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)

J. Sterne, P. Reiss, T. Sterling, 2017, Clinical Infectious Diseases.

Antiretroviral therapy in HIV-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?

G. Ippolito, P. Pezzotti, A. Monforte, 2004, European Journal of Epidemiology.

Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)

Stefan Esser, Josip Begovac, Jens D. Lundgren, 2013, PloS one.

Cancer risk and use of PI or NNRTI-based combination antiretroviral therapy (cART): The D:A:D Study

C. Sabin, A. Phillips, P. Reiss, 2013 .

Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation

J. Sterne, J. Miro, P. Reiss, 2018, Journal of the International AIDS Society.

Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?

A. Antinori, A. De Luca, A. Monforte, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program

R. Bruno, V. Vullo, A. Antinori, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence and outcomes of pregnancies in women living with HIV over a 20-year period: The EuroSIDA study, 1996 to 2015.

A. Mocroft, M. Battegay, D. Raben, 2021, AIDS.

Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?

O. Kirk, C. Sabin, A. Phillips, 2016, AIDS.

Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma

A. Mocroft, C. Sabin, M. Battegay, 2017, Journal of the National Cancer Institute.

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

R. Weber, P. Reiss, J. Lundgren, 2012, Journal of the International AIDS Society.

Predicting the short-term risk of diabetes in HIV-positive patients

R. Weber, P. Reiss, J. Lundgren, 2012 .

Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically-suppressive cART.

S. Romagnoli, C. Tincati, G. Marchetti, 2016, AIDS (London).

Immunophenotype and function of CD38-expressing CD4+ and CD8+ T cells in HIV-infected patients undergoing suppressive combination antiretroviral therapy.

C. Tincati, G. Marchetti, A. Monforte, 2014, The Journal of infectious diseases.

Immune Activation, Inflammation and HIV DNA after 96 Weeks of ATV/r Monotherapy: A MODAt Substudy

C. Tincati, G. Marchetti, A. Monforte, 2018, Antiviral therapy.

Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy

A. Antinori, A. De Luca, A. Cingolani, 2000, AIDS.

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral‐experienced patients in advanced stages of HIV‐1 infection

M. Moroni, A. Monforte, M. Musicco, 1998, AIDS.

Vertebral fractures in AIDS patients within 6 months from highly active antiretroviral therapy initiation: two case reports.

A. Monforte, P. Cicconi, T. Bini, 2008, AIDS.

Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort

A. Giacomelli, A. Cingolani, M. Bassetti, 2021, Journal of acquired immune deficiency syndromes.

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.

B. Clotet, J. Martinez-Picado, C. Katlama, 2009, The Journal of infectious diseases.

Inconsistent condom use among HIV-positive women in the “Treatment as Prevention Era”: data from the Italian DIDI study

A. Monforte, D. Francisci, P. Cicconi, 2013, Journal of the International AIDS Society.

Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.

Anne M Johnson, A. Mocroft, O. Kirk, 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Real world efficacy of dolutegravir plus lamivudine in PLWH with undetectable viral load after previous failures.

A. Antinori, P. Lorenzini, C. Mussini, 2022, Journal of global antimicrobial resistance.

Delayed HIV diagnosis an d initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord The Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

A. Monforte, 2014 .

Sexual dysfunction in HIV infection

A. Antinori, A. Monforte, M. Trotta, 2007, The Lancet.

Physician Estimates of Adherence and the Patient‐Physician Relationship as a Setting to Improve Adherence to Antiretroviral Therapy

A. Wu, A. Antinori, N. Abrescia, 2002, Journal of acquired immune deficiency syndromes.

Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.

A. Monforte, B. Castelnuovo, F. Adorni, 2000 .

The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2016, Journal of global antimicrobial resistance.

Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals

A. Mocroft, R. Weber, C. Sabin, 2016, AIDS.

Insulin resistance affects early virologic response in HIV-infected subjects treated for hepatitis C infection.

C. Tincati, A. Monforte, P. Cicconi, 2008, Journal of acquired immune deficiency syndromes.

Noninfectious HIV-related comorbidities and HAART toxicities: choosing alternative antiretroviral strategies

C. Tincati, A. Monforte, L. Gazzola, 2010 .

Health system capacity to report on indicators fostering integrated people-centred HIV care: findings from six European countries

J. Lazarus, A. Monforte, N. Azzopardi-Muscat, 2019, International Journal of Integrated Care.

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration

N. Pantazis, B. Masquelier, A. Monforte, 2013, PloS one.

Economic evaluation of HIV treatments: the I.CO.N.A. cohort study.

G. Baio, F. Pammolli, A. Bonaccorsi, 2004, Health policy.

Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV

J. Lazarus, C. Sabin, S. Buchbinder, 2021, Nature Communications.

Time spent with viral load≤200 copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era.

A. Antinori, A. Cingolani, G. Marchetti, 2021, AIDS.

Parameter estimates for trends and patterns of excess mortality among persons on ART in high-income european settings.

J. Sterne, M. Gill, M. Cavassini, 2019, AIDS.

Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens.

V. Vullo, P. Pezzotti, A. Monforte, 2001, AIDS.

Virologic Correlates of Adherence to Antiretroviral Medications and Therapeutic Failure

F. Ceccherini‐Silberstein, V. Vullo, A. Antinori, 2002, Journal of acquired immune deficiency syndromes.

Correlates and predictors of adherence to HAART: overview of published literature.

P. Narciso, P. Noto, A. Monforte, 2002 .

Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine

Anne M Johnson, Andrew N. Phillips, Reggio Emilia, 1994 .

Discontinuation of Primary Prophylaxis for Pneumocystis carinii Pneumonia and Toxoplasmic Encephalitis in Human Immunodeﬁciency Virus Type I– Infected Patients: The Changes in Opportunistic Prophylaxis Study for the Changes in Opportunistic Prophylaxis (CIOP)

M. Moroni, F. Chiodo, A. Antinori, 2022 .

Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study

S. Lazzaroni, E. Buscarini, G. Spinzi, 2018 .

Natural history of HIV-control since seroconversion

C. Sabin, M. Prins, A. Monforte, 2013, AIDS.

Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.

A. Antinori, A. De Luca, C. Mussini, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.

A. Monforte, P. Cicconi, F. Adorni, 2006, AIDS research and human retroviruses.

Is Moderate HIV Viremia Associated With a Higher Risk of Clinical Progression in HIV-Infected People Treated With Highly Active Antiretroviral Therapy: Evidence From the Italian Cohort of Antiretroviral-Naive Patients Study

D. Santoro, A. Monforte, A. Lepri, 2006, Journal of acquired immune deficiency syndromes.

Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.

R. Hogg, A. Phillips, B. Ledergerber, 2004, The Journal of infectious diseases.

Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations

A. Monforte, P. Cicconi, F. Adorni, 2002, Antiviral therapy.

Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2019, Antiviral therapy.

Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies

J. Sterne, A. Phillips, F. Dabis, 2013, AIDS.

Prevalence of prolonged amenorrhea in HIV-infected women: results from the Italian DIDI study.

G. d’Ettorre, A. Monforte, P. Cicconi, 2012, Journal of acquired immune deficiency syndromes.

Mpox in people with advanced HIV infection: a global case series

B. Clotet, P. Cahn, J. Blanco, 2023, The Lancet.

Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA)

A. Antinori, P. Cinque, P. Lorenzini, 2011, Journal of NeuroVirology.

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

A. Mocroft, C. Sabin, P. Reiss, 2016, AIDS.

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

F. Montagnini, M. Giacomini, G. Innocenti, 2020, Journal of Translational Medicine.

Simplification of Protease Inhibitor-Containing Regimens with Efavirenz, Nevirapine or Abacavir: Safety and Efficacy Outcomes

C. Mussini, A. Monforte, B. Castelnuovo, 2003, Antiviral therapy.

The presence of resistance‐associated mutations in reverse transcriptase gene is associated with cerebrospinal fluid HIV‐1 escape: A multicentric retrospective analysis

G. d’Ettorre, A. Antinori, F. Bai, 2023, Journal of medical virology.

Reduced levels of CD4 cell spontaneous apoptosis in human immunodeficiency virus-infected patients with discordant response to protease inhibitors.

A. Monforte, A. Riva, M. Galli, 2002, The Journal of infectious diseases.

All-cause mortality in treated HIV-infected adults with CD4 5500/mm compared with the general population: evidence from a large European observational cohort collaborationy

A. Mocroft, O. Kirk, M. Egger, 2022 .

Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study.

J. Sterne, P. Reiss, T. Sterling, 2018, AIDS.

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study

O. Kirk, R. Weber, C. Sabin, 2016, European journal of preventive cardiology.

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study

A. Antinori, C. Mussini, A. Monforte, 2016, Drug design, development and therapy.

CD 4 : CD 8 Ratio and CD 8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy : The Antiretroviral Therapy Cohort Collaboration ( ARTCC )

J. Sterne, P. Reiss, T. Sterling, 2017 .

Highlights on HIV eradication in 2013.

A. Lazzarin, G. Marchetti, A. Monforte, 2014, AIDS.

Osteoporosis in HIV-infected subjects: a combined effect of highly active antiretroviral therapy and HIV itself?

F. Sardanelli, A. Monforte, A. Fausto, 2005, Journal of acquired immune deficiency syndromes.

Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy

A. Antinori, C. Mussini, A. Tavelli, 2021, Journal of clinical medicine.

Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study group

R. Weber, A. Phillips, P. Reiss, 2006 .

Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.

A. Monforte, P. Cicconi, T. Bini, 2006, AIDS research and human retroviruses.

Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders : Case Reports of A New Computer-Based Restorative Approach In 3 Hiv-Positive Cart-Treated Patients

F. Bai, E. Vegni, G. Marchetti, 2016 .

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis

J. Sterne, A. Mocroft, P. Reiss, 2016, AIDS.

Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus-Related Anal Dysplastic Lesions.

C. Tincati, G. Marchetti, A. Monforte, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison

A. Antinori, A. Monforte, P. Cicconi, 2005, Antiviral therapy.

Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy

A. Antinori, A. Monforte, M. Shanyinde, 2022, Pathogens and global health.

Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA cohort over the period 1996-2001.

A. Monforte, P. Grossi, C. Perno, 2004, Journal of acquired immune deficiency syndromes.

Cerebrovascular disease in highly active antiretroviral therapy-treated individuals: incidence and risk factors.

A. Monforte, M. Bongiovanni, 2005, Journal of neurovirology.

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.

P. Narciso, A. Phillips, A. De Luca, 2006, The Journal of infectious diseases.

Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study.

A. Phillips, C. Mussini, A. Monforte, 2003, Journal of acquired immune deficiency syndromes.

Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy

M. Magnani, G. Marchetti, A. Monforte, 2010, PloS one.

Serious clinical events in HIV-positive persons with chronic kidney disease (CKD).

A. Mocroft, O. Kirk, R. Weber, 2019, AIDS.

Impact of Mutations Conferring Reduced Susceptibility to Lamivudine on the Response to Antiretroviral Therapy

M. Moroni, P. Narciso, G. Ippolito, 2000, Antiviral therapy.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

J. Sterne, A. Sabin, A. Mocroft, 2018, HIV medicine.

Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.

F. Baldanti, R. Maserati, D. Lilleri, 2001 .

Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder

G. Parati, R. Scala, M. Girardis, 2023, Respiratory Research.

Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration

J. Sterne, M. Egger, R. Hogg, 2002 .

Effects of Different Interventions to Improve ART-associated Dyslipidemia

O. Kirk, R. Weber, C. Sabin, 2006 .

CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus

Anne M Johnson, C. Morrison, P. Vanhems, 2017, The Journal of antimicrobial chemotherapy.

Association between dideoxynucleoside analogues (d-Drugs) and end-stage liver disease (ESLD)

O. Kirk, C. Sabin, A. Phillips, 2014 .

Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin.

A. Monforte, S. Ferrero, R. Ranieri, 2006, AIDS.

Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.

R. Bruno, R. Maserati, V. Vullo, 2005, AIDS reviews.

sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies

J. Sterne, H. Günthard, C. Sabin, 2023, medRxiv : the preprint server for health sciences.

U . S . A . : A modelling study

T. Hallett, A. Mammone, A. Antinori, 2019 .

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program.

R. Bruno, V. Vullo, A. Antinori, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Role of HCV viraemia and HCV genotype in the immune recovery from HAART in a cohort of antiretroviral naïve HIV-infected individuals

G. Ippolito, M. Capobianchi, F. Carletti, 2005 .

Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test.

F. Ceccherini‐Silberstein, A. Antinori, C. Mussini, 2010, Journal of acquired immune deficiency syndromes.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients : a collaborative analysis of 18 HIV cohort studies

S. Cole, J. Sterne, R. Hogg, 2009 .

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion

C. Morrison, P. Vanhems, A. Kamali, 2017, HIV medicine.

Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.

P Pezzotti, A Cozzi-Lepri, A N Phillips, 2001, The Journal of infectious diseases.

Predictors of Having a Resistance Test following Confirmed Virological Failure of Combination Antiretroviral Therapy: Data from Eurosida

Z. Fox, B. Clotet, A. Phillips, 2011, Antiviral therapy.

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

A. Mocroft, O. Kirk, H. Furrer, 2001, The New England journal of medicine.

Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The effectiveness of indicator disease-based HIV testing across Europe - results from a prospective multi-centre study

M. Jakobsen, B. Gazzard, A. Mocroft, 2015 .

New-onset delusions and hallucinations in patients infected with HIV.

A. d’Arminio Monforte, A. Monforte, A. Alciati, 2001, Journal of psychiatry & neuroscience : JPN.

Declining Levels of Rescued Lymphoproliferative Response to Human Cytomegalovirus (HCMV) in AIDS Patients With or Without HCMV Disease Following Long‐Term HAART

F. Baldanti, R. Maserati, D. Lilleri, 2001, Journal of acquired immune deficiency syndromes.

Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.

A. Mocroft, O. Kirk, M. Dietrich, 1999, AIDS.

Antiretroviral Drugs Associated with Chronic ALT Elevations in Persons without HCV and HBV Infection

R. Weber, C. Sabin, A. Phillips, 2015 .

Hepatitis B virus-associated coinfection and superinfection with delta agent: indistinguishable disease with different outcome.

M. Moroni, A. d’Arminio Monforte, A. Monforte, 1985, The Journal of infectious diseases.